Recombinant human growth hormone — clinically approved for specific deficiencies, frequently misused for anti-aging. Here’s how it actually works and what responsible access looks like.
Human growth hormone (HGH, somatropin) is a 191-amino-acid recombinant protein produced by DNA technology to match endogenous pituitary growth hormone. It’s sold under brand names including Genotropin, Humatrope, Norditropin, Omnitrope, and Saizen.
HGH is prescription-only in the US and FDA approved for specific indications: adult and pediatric growth hormone deficiency, certain short-stature syndromes, HIV-associated wasting, and short bowel syndrome. Prescribing HGH for anti-aging or athletic enhancement is illegal under federal law.
FDA approved for defined indications. Not a DEA-scheduled controlled substance, but distribution for any use other than an FDA-approved indication is a federal crime under 21 USC §333(e), punishable by up to 5 years imprisonment. WADA prohibited (S2.1). StackTrax does not sell or facilitate HGH.
Binds GH receptors primarily in the liver and peripheral tissues. Liver response produces IGF-1, which mediates most of the anabolic and metabolic effects downstream.
Serum IGF-1 is the primary measured outcome of HGH therapy and the standard biomarker for titration (Endocrine Society 2011, PMID 21602453). It's the key driver of muscle growth, tissue repair, and bone density effects.
HGH directly stimulates fat breakdown in adipose tissue via its own receptors — independent of IGF-1. This is a mechanism secretagogues (sermorelin, CJC+Ipa) preserve.
Exogenous HGH suppresses the pituitary’s own pulsatile GH output via IGF-1 negative feedback on the somatotropic axis (hypothalamic GHRH → pituitary GH → liver IGF-1). This is why GH secretagogues (which stimulate your own pituitary) have become the preferred approach for non-deficient patients.
| Benefit | Evidence |
|---|---|
| GH deficiency | Gold-standard: restores normal growth in children, normalizes body composition and metabolism in adults (Molitch 2011, PMID 21602453) |
| Lean mass / fat loss | Measurable in deficient adults; in healthy adults Liu 2008 (PMID 18347346) found body-composition shifts but no improvement in strength or aerobic capacity, with elevated AE rates |
| Recovery / repair | IGF-1 promotes anabolic signaling in injured tissue (satellite-cell activation, collagen synthesis) — the mechanistic basis for the "recovery" framing in clinical literature |
| Sleep quality | Endogenous GH peaks during slow-wave sleep; the relationship is bidirectional. Exogenous HGH does not reliably improve sleep quality and may flatten the natural pulse |
| Bone density | Long-term BMD improvements in deficient patients on extended replacement (Johannsson 2022 KIMS, PMID 35368070) |
| Anti-aging (off-label) | Rudman 1990 (PMID 2355952) had no placebo arm, no strength or QoL endpoints, and was disavowed by NEJM in a 2003 editorial (Vance, PMID 12606731). Follow-up work shows modest body-composition effect with significant AE burden at anti-aging doses |
For non-deficient adults seeking GH-pathway benefits, growth hormone secretagogue peptides (sermorelin, CJC+ipamorelin, tesamorelin) offer most of the upside with fewer side effects and without axis shutdown.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreePer Endocrine Society 2011 (PMID 21602453); the guideline cautions against driving IGF-1 to the upper limit. AACE/ACE 2019 (Yuen, PMID 31760824) recommends age-stratified starting doses — younger adults may start higher (0.4–0.5 mg/day under 30).
Some integrative clinics use 1–2 IU/day in older adults. These ranges have no support in FDA labels or major society guidelines, and Liu 2008 (PMID 18347346) found supraphysiologic GH in healthy adults produces body-composition shifts without strength or aerobic gains, with elevated AE rates. Peptide alternatives (CJC+Ipa, tesamorelin) are increasingly preferred at this dose range.
IGF-1 (primary), fasting glucose, HbA1c, lipids, thyroid panel. Many providers also monitor IGFBP-3. Frequency: baseline, 6–8 weeks after starting or adjusting, then every 3–6 months (Endocrine Society 2011, PMID 21602453).
FDA-approved HGH is dispensed as pre-filled pen cartridges (Genotropin, Norditropin, Humatrope pens) or multi-dose vials with dedicated diluent. Unlike research peptides, you do not reconstitute with bacteriostatic water — the manufacturer’s diluent is the only appropriate reconstitution fluid.
Pre-filled with a typical HGH / Somatropin setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
HGH elevates IGF-1. Active malignancy is an absolute contraindication. History of malignancy is a relative caution — current consensus (GHRS 2022, Boguszewski, PMID 35319491) supports individualized risk-benefit assessment with the treating oncology team. In childhood cancer survivors, a small second-neoplasm signal (largely meningioma after cranial radiation) has been reported (He 2022 meta-analysis, PMID 35529328).
HGH / Somatropin is a prescription medication. StackTrax does not sell, prescribe, or facilitate purchase of prescription drugs.
Find a clinician who can order baseline lab work, screen for contraindications, monitor your response, and adjust dosing over time. Options to consider:
Before starting, you’ll typically want:
Avoid sources that offer prescription medications without labs, medical history, or licensed-provider oversight. If a telehealth service promises a prescription after a 5-minute questionnaire, that’s a red flag.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeYes — for defined indications only. Recombinant somatropin is FDA approved for pediatric growth hormone deficiency, adult GHD, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, short bowel syndrome, AIDS wasting, and several other rare indications. Brand names include Genotropin, Norditropin, Humatrope, Saizen, Omnitrope, Zomacton, Skytrofa (lonapegsomatropin, long-acting), Ngenla (somatrogon), and Sogroya (somapacitan). Off-label use for anti-aging, body composition, or athletic enhancement is NOT FDA approved and carries legal risk: distribution of HGH for non-approved uses is restricted under 21 USC §333(e), which classifies non-prescribed HGH distribution as a federal offense punishable by fines and imprisonment.
Approved adult GHD label dose is approximately 0.2 mg/day subcutaneously (Genotropin), titrated to IGF-1 levels. Community off-label "anti-aging" doses commonly cited are 1–4 IU/day (approximately 0.33–1.3 mg/day, given the 3 IU = 1 mg conversion). Higher community doses (5+ IU/day) sit well above the approved adult GHD label and substantially increase side effect risk (insulin resistance, edema, carpal tunnel, joint pain).
Reconstitution depends heavily on the specific product — most FDA-approved pen presentations come with their own diluent and procedure (do NOT use community BAC-water protocols on prefilled pens). For loose-vial research-grade HGH (typically 10 IU per vial): 10 IU + 1 mL of bacteriostatic water yields 10 IU/mL. A 2 IU dose draws to 0.20 mL (20 units on a 100-unit insulin syringe). 1 mg of somatropin ≈ 3 IU by WHO standard.
Per FDA labels: fluid retention/edema (especially in the first weeks), arthralgia, myalgia, carpal tunnel syndrome, paresthesia, insulin resistance (causing fasting glucose increases and sometimes overt T2DM), elevated triglycerides, and benign intracranial hypertension (rare). Long-term registry data (KIMS, HypoCCS) shows acceptable safety in adults treated for GHD at approved doses; safety at higher off-label doses is less well-characterized. Cancer recurrence/incidence concerns have been studied extensively without consistent signal in approved-indication use.
IGF-1 elevation is detectable within days. Subjective effects (sleep depth, recovery) often reported in the first 2–4 weeks. Body composition changes (lean mass increase, fat mass decrease) typically accumulate over 3–6 months of consistent daily dosing. Subcutaneous Tmax is 4–5 hours; terminal half-life is short (~2.5–2.8 hours) but the IGF-1 response sustains for 24+ hours, which is why daily dosing produces near-continuous IGF-1 elevation.
Yes. Somatropin and all recombinant growth hormones are prohibited at all times under WADA S2.2 (Growth Hormone and its analogues). The detection windows of modern GH isoform assays and the GH biomarker test catch use in many cases. No therapeutic-use exemption available for athletes outside genuine GHD diagnosis.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.